Inotiv, INC. (NOTV) — SEC Filings

Overview

Inotiv, INC. (NOTV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Dec 5, 2025: Inotiv, Inc. (NOTV) filed its 10-K for the fiscal year ended September 30, 2025, revealing significant financial and operational challenges. The company, a contract research organization, reported conditions that raise substantial doubt about its ability to continue as a going concern, stemming from

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 1 bearish, 27 neutral, 1 mixed. The dominant filing sentiment for Inotiv, INC. is neutral.

Filing Type Overview

Inotiv, INC. (NOTV) has filed 2 10-K, 18 8-K, 5 10-Q, 2 DEF 14A, 1 10-Q/A, 1 SC 13D/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (29)

• Inotiv Faces Going Concern Doubts Amidst Debt, Weak Controls, and NHP Supply Woes — 10-K · Dec 5, 2025 Risk: high
  Inotiv, Inc. (NOTV) filed its 10-K for the fiscal year ended September 30, 2025, revealing significant financial and operational challenges. The company, a cont
• 8-K Filing — 8-K · Dec 3, 2025
• Inotiv, Inc. Files 8-K on Financials — 8-K · Nov 17, 2025 Risk: low
  Inotiv, Inc. filed an 8-K on November 17, 2025, to report on its results of operations and financial condition, as well as to file financial statements and exhi
• Inotiv, Inc. Files 8-K Under 'Other Events' — 8-K · Sep 25, 2025 Risk: low
  Inotiv, Inc. filed an 8-K on September 25, 2025, reporting an event that occurred on August 21, 2025. The filing is categorized under 'Other Events' and does no
• Inotiv, Inc. Files 8-K for Undisclosed Event — 8-K · Aug 18, 2025 Risk: medium
  Inotiv, Inc. filed an 8-K on August 18, 2025, reporting an "Other Event" that occurred on August 8, 2025. The filing does not provide specific details about the
• Inotiv Narrows Q3 Loss to $13.7M on 7.3% Revenue Growth — 10-Q · Aug 7, 2025 Risk: high
  Inotiv, Inc. reported a net loss of $13.7 million for the three months ended June 30, 2025, a significant improvement from the $20.1 million net loss in the pri
• Inotiv, Inc. Files 8-K on Financials — 8-K · Aug 6, 2025 Risk: low
  Inotiv, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition, and including financial statements and exhibits. Th
• Inotiv, Inc. Files 8-K Report on Other Events — 8-K · Jun 4, 2025 Risk: low
  On June 2, 2025, Inotiv, Inc. filed an 8-K report. The filing pertains to "Other Events" and was submitted on June 4, 2025. The company, previously known as BIO
• Inotiv, Inc. Files 8-K for Routine Disclosures — 8-K · May 29, 2025 Risk: low
  Inotiv, Inc. filed an 8-K on May 29, 2025, primarily to disclose information under Regulation FD and to file financial statements and exhibits. The filing does
• Inotiv, Inc. Files 10-Q for Period Ending March 31, 2025 — 10-Q · May 8, 2025 Risk: medium
  Inotiv, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results for the second quarter and the first six months of its
• Inotiv, Inc. Files 8-K on Financials — 8-K · May 7, 2025 Risk: low
  Inotiv, Inc. filed an 8-K on May 7, 2025, reporting on its results of operations and financial condition, and including financial statements and exhibits. The f
• Inotiv, Inc. Files 8-K: Director Changes, Officer Compensation, Shareholder Votes — 8-K · Mar 13, 2025 Risk: medium
  On March 13, 2025, Inotiv, Inc. filed an 8-K report detailing several key events. These include the departure of directors or certain officers, the election of
• Inotiv, Inc. Files 8-K Reporting Other Events — 8-K · Feb 18, 2025 Risk: low
  Inotiv, Inc. filed an 8-K on February 18, 2025, reporting an event that occurred on February 14, 2025. The filing is categorized under 'Other Events' and 'Finan
• Inotiv, Inc. Files Q1 2025 10-Q Report — 10-Q · Feb 6, 2025 Risk: medium
  Inotiv, Inc. filed its 10-Q for the period ending December 31, 2024. The company, headquartered in West Lafayette, Indiana, operates in the commercial physical
• Inotiv, Inc. Files 8-K on Financials — 8-K · Feb 5, 2025 Risk: low
  Inotiv, Inc. filed an 8-K on February 5, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and
• Inotiv Inc. Files DEF 14A for FY2025 — DEF 14A · Jan 23, 2025 Risk: medium
  Inotiv, Inc. filed a DEF 14A on January 23, 2025, for the fiscal year ending September 30, 2025. The filing details executive compensation and corporate governa
• Inotiv, Inc. Files 8-K: Material Definitive Agreement — 8-K · Dec 18, 2024 Risk: medium
  On December 17, 2024, Inotiv, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also r
• Inotiv, Inc. Files 2024 10-K Report — 10-K · Dec 4, 2024 Risk: medium
  Inotiv, Inc. filed its 10-K for the fiscal year ending September 30, 2024, reporting on its operations in biological and physical research. The filing details f
• Inotiv, Inc. Files 8-K on Financials — 8-K · Dec 3, 2024 Risk: low
  Inotiv, Inc. filed an 8-K on December 3, 2024, to report on its results of operations and financial condition, and to file financial statements and exhibits. Th
• Inotiv Secures $100M Credit Facility — 8-K · Sep 19, 2024 Risk: medium
  On September 13, 2024, Inotiv, Inc. entered into a Material Definitive Agreement, specifically a Credit Agreement with MidCap Financial Trust, which provides a
• Inotiv, Inc. Files Q3 2024 10-Q Report — 10-Q · Aug 9, 2024 Risk: medium
  Inotiv, Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance. The company, formerly known as BIOANALYTICAL SYSTEMS IN
• Inotiv, Inc. Files 8-K on Financials — 8-K · Aug 8, 2024 Risk: low
  Inotiv, Inc. filed an 8-K on August 8, 2024, to report on its results of operations and financial condition, and to file financial statements and exhibits. The
• Inotiv, Inc. Enters Material Definitive Agreement — 8-K · Jun 4, 2024 Risk: medium
  On June 2, 2024, Inotiv, Inc. entered into a material definitive agreement, specifically a credit agreement, which creates a direct financial obligation for the
• Inotiv, Inc. Files 10-Q/A Amendment for Period Ending March 31, 2024 — 10-Q/A · May 16, 2024 Risk: low
  Inotiv, Inc. (NOTV) filed a Amended Quarterly Report (10-Q/A) with the SEC on May 16, 2024. Inotiv, Inc. filed an amendment (10-Q/A) on May 16, 2024, for the pe
• Inotiv, Inc. Files 8-K on Financials — 8-K · May 15, 2024 Risk: low
  Inotiv, Inc. filed an 8-K on May 15, 2024, reporting results of operations and financial condition. The filing details financial statements and exhibits related
• Jermyn Street Associates Ups Inotiv Stake — SC 13D/A · Apr 3, 2024 Risk: medium
  Jermyn Street Associates LLC, on April 3, 2024, filed an amendment to its Schedule 13D regarding Inotiv, Inc. The filing indicates a change in beneficial owners
• Inotiv Acquired by Roark Capital Affiliate — 8-K · Mar 19, 2024 Risk: medium
  Inotiv, Inc. announced on March 14, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of Roark Capital. The transaction is ex
• Inotiv, Inc. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 7, 2024 Risk: medium
  Inotiv, Inc. (NOTV) filed a Quarterly Report (10-Q) with the SEC on February 7, 2024. Inotiv, Inc. reported financial results for the quarter ended December 31,
• Inotiv, Inc. Files Definitive Proxy Statement for 2024 Annual Meeting — DEF 14A · Jan 26, 2024 Risk: medium
  Inotiv, Inc. (NOTV) filed a Proxy Statement (DEF 14A) with the SEC on January 26, 2024. Inotiv maintained similar revenue in its RMS operations despite reduced

Risk Profile

Risk Assessment: Of NOTV's 28 recent filings, 2 were flagged as high-risk, 14 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Inotiv, INC.'s most recent 10-K filing (Dec 5, 2025):

• Revenue: Not Disclosed
• Net Income: Not Disclosed
• EPS: Not Disclosed
• Debt-to-Equity: Not Disclosed
• Cash Position: Not Disclosed
• Operating Margin: Not Disclosed
• Total Assets: Not Disclosed
• Total Debt: Not Disclosed

Key Executives

• Robert W. Leasure Jr.
• Beth A. Taylor
• John E. Sagartz
• John Papachristos
• Donna M. Bryan

Industry Context

Inotiv operates as a contract research organization (CRO) serving the pharmaceutical and medical device industries. The CRO market is competitive, driven by the increasing outsourcing of R&D activities by life sciences companies seeking to reduce costs and accelerate drug development timelines. Key trends include demand for specialized services, advanced technologies, and reliable animal models. However, the industry is also subject to stringent regulatory oversight and ethical considerations regarding animal research.

Top Tags

8-k (9) · financial-reporting (7) · 10-Q (4) · 8-K (3) · SEC Filing (3) · financials (3) · Inotiv (3) · regulatory-filing (2) · other-events (2) · reporting (2)

Key Numbers

• Market Value of Non-Affiliate Equity: $71.3M — As of March 31, 2025, indicating the public float's valuation.
• Common Shares Outstanding: 34.4M — As of November 21, 2025, representing the total shares available.
• Fiscal Year End: 2025 — The period covered by this 10-K filing, ending September 30, 2025.
• Year Operations Began: 1975 — Original founding year as Bioanalytical Systems, Inc.
• Year of Name Change: 2021 — Company changed name from Bioanalytical Systems, Inc. to Inotiv, Inc. on March 18, 2021.
• Net Loss: $13.7M — Improved from $20.1M in prior year, but still a significant loss.
• Total Revenue: $35.2M — Increased 7.3% from $32.8M year-over-year, showing top-line growth.
• Revenue Growth: 7.3% — Positive growth indicating increased sales of services and products.
• Accumulated Deficit: $205.3M — A large deficit indicating historical unprofitability and financial risk.
• Service Revenue: $30.5M — Grew 8.5% year-over-year, driving overall revenue increase.
• Product Revenue: $4.7M — Increased 1.7% year-over-year, contributing to overall revenue.
• SEC File Number: 0-23357 — Identifies the specific SEC filing for Inotiv, Inc.
• IRS Employer Identification No.: 35-1345024 — Tax identification number for Inotiv, Inc.
• Fiscal Quarter: Q1 2025 — Reporting period covered by the 10-Q
• Conformed Period of Report: 20250313 — Fiscal year end for reporting

Related Companies

EDIT

Frequently Asked Questions